

10/038335
Search results

Freeform Search

Database:

US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Term:

oligonucleotide\$ near10 telomere near5 length
near5 (modulat\$ or alter\$ or change\$)

Display:

100 Documents in Display Format: Starting with Number 1

Generate: Hit List Hit Count Side by Side Image

Search **Clear** **Interrupt**

Search History

DATE: Wednesday, May 25, 2005 [Printable Copy](#) [Create Case](#)

<u>Set</u>	<u>Name</u>	<u>Query</u>	<u>Hit</u>	<u>Set</u>
			<u>Count</u>	<u>Name</u>
side by side				result set
		DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR		
<u>L16</u>	L15	and guanine near rich	18	<u>L16</u>
<u>L15</u>	GGGG	or G4	39143	<u>L15</u>
<u>L14</u>	L12	and (chimeric or phosphoro\$ or phosphonate or chiral or phosphoramidate or sugar)	50	<u>L14</u>
<u>L13</u>	L12	and (chimeric or phosphoro\$ or phosphonate or chiral or phosphoramidate)	49	<u>L13</u>
<u>L12</u>	l8	and (modified) near5 oligonucleotide\$	57	<u>L12</u>
<u>L11</u>	L10	and (modified or phosphoro\$)	31	<u>L11</u>
<u>L10</u>	L9	and telomere\$	42	<u>L10</u>
<u>L9</u>	G	near quadruplex or G-quadruplex	80	<u>L9</u>
<u>L8</u>	oligonucleotide\$	and telomere near5 length near5 (modulat\$ or alter\$ or change\$)	119	<u>L8</u>
<u>L7</u>	oligonucleotide\$	near10 telomere near5 length near5 (modulat\$ or alter\$ or change\$)	6	<u>L7</u>
<u>L6</u>	oligonucleotide\$	and telomere near5 length near5 modulat\$	77	<u>L6</u>

<u>L5</u>	oligonucleotide\$ near10 telomere near5 length near5 modulat\$	4	<u>L5</u>
<u>L4</u>	telomere near5 length near5 modulat\$	91	<u>L4</u>
<u>L3</u>	L1 and N	2	<u>L3</u>
<u>L2</u>	L1 and thiouracil	1	<u>L2</u>
<u>L1</u>	20030096776	2	<u>L1</u>

END OF SEARCH HISTORY

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 57 of 57 returned.**

- 1. [20050074825](#). 08 Jul 03. 07 Apr 05. Tankyrase H, compositions involved in the cell cycle and methods of use. Luo, Ying, et al. 435/7.23; G01N033/574.
- 2. [20050013825](#). 24 Jun 04. 20 Jan 05. Vaccine containing the catalytic subunit of telomerase for treating cancer. Cech, Thomas R., et al. 424/185.1; 435/183 435/320.1 435/325 435/69.1 530/350 536/23.5 A61K039/00 C07H021/04 C12P021/04 C12N009/00.
- 3. [20040253701](#). 07 Jun 04. 16 Dec 04. Protein and peptide fragments from mouse telomerase reverse transcriptase. Morin, Gregg B., et al. 435/199; 435/6 530/388.26 C12Q001/68 C12N009/22 C07K016/40.
- 4. [20040247613](#). 24 Jun 04. 09 Dec 04. Treating cancer using a telomerase vaccine. Cech, Thomas R., et al. 424/185.1; A61K039/00.
- 5. [20040242529](#). 24 Jun 04. 02 Dec 04. Vector encoding inactivated telomerase for treating cancer. Cech, Thomas R., et al. 514/44; 435/320.1 435/455 A61K048/00 C12N015/85.
- 6. [20040198659](#). 22 Oct 03. 07 Oct 04. Therapy and diagnosis of conditions related to telomere length and/or telomerase activity. West, Michael D., et al. 514/12; 435/6 514/44 A61K048/00 C12Q001/68.
- 7. [20040115716](#). 15 Oct 03. 17 Jun 04. Methods of obtaining active antisense compounds. Freier, Susan M., et al. 435/6; C12Q001/68.
- 8. [20040072787](#). 29 Sep 03. 15 Apr 04. Telomerase reverse transcriptase transcriptional regulatory sequences and methods of using. Morin, Gregg B., et al. 514/44; 435/456 A61K048/00 C12N015/86.
- 9. [20040038244](#). 21 Aug 03. 26 Feb 04. Assays for alternative lengthening of telomeres. Reddel, Roger Robert, et al. 435/6; 435/320.1 435/325 435/69.1 530/358 536/23.5 C12Q001/68 C07H021/04.
- 10. [20030207831](#). 28 May 02. 06 Nov 03. Antisense modulation of telomeric repeat binding factor 2 expression. Monia, Brett P., et al. 514/44; 435/375 536/23.2 A61K048/00 C07H021/04.
- 11. [20030204069](#). 20 Dec 02. 30 Oct 03. Segments of the human gene for telomerase reverse transcriptase. Morin, Gregg B., et al. 536/23.2; 435/199 435/320.1 435/325 435/456 435/6 435/69.1 C12Q001/68 C07H021/04 C12N009/22 C12P021/02 C12N005/06 C12N015/86.
- 12. [20030190638](#). 29 Aug 02. 09 Oct 03. Methods of screening for compounds that derepress or increase telomerase activity. West, Michael D., et al. 435/6; 424/450 424/93.7 435/372 514/1 C12Q001/68 A61K031/00 A61K045/00 A61K009/127 C12N005/08.
- 13. [20030175766](#). 18 Dec 02. 18 Sep 03. Therapy and diagnosis of conditions related to telomere length and/or telomerase activity. West, Michael D., et al. 435/6; 514/44 C12Q001/68 A61K048/00.
- 14. [20030148988](#). 03 Jan 03. 07 Aug 03. Telomere-encoding synthetic DNA nanocircles, and their use for the elongation of telomere repeats. Kool, Eric T.. 514/44; 435/320.1 435/6 536/23.2

A61K048/00 C12Q001/68 C07H021/04.

- 15. 20030100093. 11 Jan 02. 29 May 03. Human telomerase catalytic subunit: diagnostic and therapeutic methods. Cech, Thomas R., et al. 435/199; 435/320.1 435/325 435/368 435/69.1 536/23.2 C12N009/22 C07H021/04 C12P021/02 C12N005/08.
- 16. 20030096776. 02 Jan 02. 22 May 03. Modulation of telomere length by oligonucleotides having a G-core sequence. Hanecak, Ronnie C., et al. 514/44; 435/455 536/23.1 A61K048/00 C12N015/85 C07H021/04.
- 17. 20030096344. 11 Jan 02. 22 May 03. Human telomerase catalytic subunit: diagnostic and therapeutic methods. Cech, Thomas R., et al. 435/69.1; 424/146.1 435/199 435/320.1 435/325 C12P021/02 C12N005/06 A61K039/395 C12N009/22.
- 18. 20030032769. 05 Oct 01. 13 Feb 03. Second mammalian tankyrase. Morin, Gregg B., et al. 530/300; 536/23.5 536/24.31 C07K002/00 C07K005/00 C07K014/00 C07K017/00 C07K004/00 C07K007/00 C07K016/00 A61K038/00 C07H021/04.
- 19. 20020127634. 05 Jun 95. 12 Sep 02. THERAPY AND DIAGNOSIS OF CONDITIONS RELATED TO TELOMERE LENGTH AND/OR TELOMERASE ACTIVITY. WEST, MICHAEL D., et al. 435/46; 356/320 436/15 436/43 436/50 436/8 G01N031/00 G01N035/00 G01N035/02 G01J003/42.
- 20. 20020045588. 07 Dec 00. 18 Apr 02. Antisense modulation of TERT expression. Monia, Brett P., et al. 514/44; 536/23.2 A61K048/00 C07H021/04.
- 21. 6887675. 25 Apr 01; 03 May 05. Tankyrase H, compositions involved in the cell cycle and methods of use. Luo, Ying, et al. 435/19; 435/15 435/183 435/194 435/196 435/252.3 435/320.1 435/4 435/6 435/69.1 530/350 536/23.2 536/23.4 536/23.5. C12N00912 C12N00916 C12O00144 C12O00148 C07H02104.
- 22. 6777203. 04 Feb 99; 17 Aug 04. Telomerase promoter driving expression of therapeutic gene sequences. Morin; Gregg B., et al. 435/69.1; 435/320.1 435/325 435/455 530/350 536/23.1 536/23.5. C12P021/06 C12N005/00 C12N015/00.
- 23. 6767719. 16 Mar 98; 27 Jul 04. Mouse telomerase reverse transcriptase. Morin; Gregg B., et al. 435/69.1; 435/320.1 435/325 435/455 530/350 536/23.1 536/23.5. C12P021/06 C12N005/00 C12N015/63 C07H021/04 C07K001/00.
- 24. 6617110. 24 Nov 00; 09 Sep 03. Cells immortalized with telomerase reverse transcriptase for use in drug screening. Cech; Thomas R., et al. 435/6; 435/194 435/29 435/325 435/69.2 536/23.2. C12G001/68 C12N009/12 C12N015/09 C12N005/00 C12Q001/02.
- 25. 6617102. 25 Oct 00; 09 Sep 03. Tankyrase H, compositions involved in the cell cycle and methods of use. Luo; Ying, et al. 435/4; 435/6 435/7.1. C12Q001/00 C12Q001/68 G01N033/53.
- 26. 6610839. 29 Sep 99; 26 Aug 03. Promoter for telomerase reverse transcriptase. Morin; Gregg B., et al. 536/24.1; 435/194 435/320.1. C07H021/04 C12N009/12 C12N015/00.
- 27. 6599728. 05 Oct 01; 29 Jul 03. Second mammalian tankyrase. Morin; Gregg B., et al. 435/194; 435/183 435/325 530/358 536/23.1. C12N009/12 C12N009/00 C12N005/00 A61K038/16 C07H021/04.

□ 28. 6589725. 25 Oct 99; 08 Jul 03. Tankyrase H, compositions involved in the cell cycle and methods of use. Luo; Ying, et al. 435/4; 435/6 435/69.1. C12Q001/00 C12Q001/68 C12P021/06.

□ 29. 6551774. 20 Aug 99; 22 Apr 03. Diagnostic methods for conditions associated with elevated cellular levels of telomerase activity. West; Michael D., et al. 435/6; 435/15 435/7.1 435/91.2 435/91.5. C12Q001/68 C12P019/34 G01N033/53 G01N033/574.

□ 30. 6492171. 07 Dec 00; 10 Dec 02. Antisense modulation of TERT expression. Monia; Brett P., et al. 435/375; 435/325 536/24.5. C07H021/04 C12Q001/68 C12N005/00.

□ 31. 6475789. 14 Aug 97; 05 Nov 02. Human telomerase catalytic subunit: diagnostic and therapeutic methods. Cech; Thomas R., et al. 435/366; 424/94.1 435/320.1 435/69.1 536/23.2. C12N005/08 C12N015/12 C07H021/04 A61K038/43.

□ 32. 6368789. 05 Jun 95; 09 Apr 02. Screening methods to identify inhibitors of telomerase activity. West; Michael D., et al. 435/6; 435/7.21 435/7.22 435/7.4 435/7.72 435/91.31. C12Q001/68 G01N033/53 C12P019/34.

□ 33. 6331399. 16 May 00; 18 Dec 01. Antisense inhibition of tert expression. Monia; Brett P., et al. 435/6; 435/325 435/375 536/23.1 536/24.5. C07H021/04 C12Q001/68 C12N005/02.

□ 34. 6300132. 17 Dec 99; 09 Oct 01. Antisense inhibition of telomeric repeat binding factor 2 expression. Monia; Brett P., et al. 435/375; 514/44 536/24.5. A61K031/711 A61K031/712 A61K031/712 C07H021/00 C12N005/00.

□ 35. 6194206. 24 Dec 97; 27 Feb 01. Use of oligonucleotide telomerase inhibitors to reduce telomere length. West; Michael D., et al. 435/375; 514/44 536/24.31. A61K031/70 C12N005/10 C07H021/00.

□ 36. 6166178. 19 Nov 97; 26 Dec 00. Telomerase catalytic subunit. Cech; Thomas R., et al. 530/324; 530/827 530/828 536/23.2 536/23.5. A61K038/00 C07K005/00 C07K007/00 C07K016/00.

□ 37. 6165789. 27 Oct 99; 26 Dec 00. Antisense modulation of hnRNP A1 expression. Monia; Brett P., et al. 435/375; 435/366 435/6 435/91.1 536/23.1 536/24.31 536/24.33 536/24.5. C12Q001/68 C07H021/04 A61K048/00 C12N015/00 C12N015/85.

□ 38. 6130088. 21 Jul 99; 10 Oct 00. Antisense modulation of telomeric repeat binding factor 1 expression. Monia; Brett P., et al. 435/375; 435/366 435/6 435/91.1 536/23.1 536/24.31 536/24.33 536/24.5. C07H021/04 C12Q001/68 C12N015/85.

□ 39. 6007989. 14 Mar 97; 28 Dec 99. Methods of screening for compounds that derepress or increase telomerase activity. West; Michael D., et al. 435/6; 435/15 435/375 435/4 435/7.2 435/91.1 435/91.2. C12Q001/68 C12P019/34.

□ 40. 5952490. 12 Jun 95; 14 Sep 99. Oligonucleotides having a conserved G4 core sequence. Hanecak; Ronnie C., et al. 536/24.5; 536/25.5. C07H021/04.

□ 41. 5840495. 07 Jun 95; 24 Nov 98. Methods for diagnosis of conditions associated with elevated levels of telomerase activity. West; Michael D., et al. 435/6; 435/325 435/375 514/44 536/23.1 536/24.1

536/24.3 536/24.5. C12Q001/68 G01N033/53.

- 42. 5834193. 07 Jun 96; 10 Nov 98. Methods for measuring telomere length. Kozlowski; Michael R., et al. 435/6; 536/24.31. C12Q001/68 C07H021/02 C07H021/04.
- 43. 5830644. 12 Nov 93; 03 Nov 98. Method for screening for agents which increase telomerase activity in a cell. West; Michael D., et al. 435/6; 435/15 435/4 435/7.2 435/91.2 436/34 436/501 436/63 436/64 436/94. C12Q001/68 C12P019/34.
- 44. 5707795. 07 Jun 95; 13 Jan 98. Therapy and diagnosis of conditions related to telomere length and/or telomerase activity. West; Michael D., et al. 435/5; 435/4 435/6 435/91.2 436/63 436/64 536/24.33. C12Q001/68 C12Q001/70 C12P019/34 C07H021/04.
- 45. 5695932. 13 May 93; 09 Dec 97. Telomerase activity assays for diagnosing pathogenic infections. West; Michael D., et al. 435/6; 435/91.1. C12Q001/68 C12P019/34.
- 46. 5693474. 07 Jun 95; 02 Dec 97. Methods for cancer diagnosis and prognosis. Shay; Jerry, et al. 435/6; 435/15 435/183 435/184 435/194 435/91.2 436/63 436/64. C12Q001/68 C12P019/34.
- 47. 5686306. 10 Nov 94; 11 Nov 97. Methods and reagents for lengthening telomeres. West; Michael D., et al. 435/346; 435/375 435/6 536/23.1. C12N005/10 C12N005/12 C07H021/00 C07H021/07.
- 48. 5686245. 07 Jun 95; 11 Nov 97. Methods for screening for agents which modulate telomere length. West; Michael D., et al. 435/6; 435/15 435/4 435/91.1 435/91.2 436/64 514/44. C12Q001/68 C12P019/34.
- 49. 5645986. 12 Nov 93; 08 Jul 97. Therapy and diagnosis of conditions related to telomere length and/or telomerase activity. West; Michael D., et al. 435/6; 435/183 435/184 435/194 435/91.2 436/63 536/24.31 536/24.33. C12Q001/68 C12P019/34 C12N009/12.
- 50. 5523389. 28 Sep 93; 04 Jun 96. Inhibitors of human immunodeficiency virus. Ecker; David J., et al. 536/23.1; 435/6 435/91.1. C12N015/11 C12Q001/68.
- 51. 5489508. 24 Mar 93; 06 Feb 96. Therapy and diagnosis of conditions related to telomere length and/or telomerase activity. West; Michael D., et al. 435/6; 435/15 435/91.1 435/91.5 436/64 536/24.33. C12Q001/68 C12P019/34 C07H021/04.
- 52. 5466576. 02 Jul 93; 14 Nov 95. Modulation of PIF-1-type helicases. Schulz; Vincent P., et al. 435/6; 435/183 435/193. C12Q001/68 C12N009/00 C12N009/10 C12N015/54.
- 53. EP001016715A1. 29 Sep 93. 05 Jul 00. Oligonucleotides having a conserved G4 core sequence. BROWN-DRIVER, VICKIE L, et al. C12N015/11; A61K031/7125.
- 54. WO009408053A1. 29 Sep 93. 14 Apr 94. OLIGONUCLEOTIDES HAVING A CONSERVED G4 CORE SEQUENCE. HANECAK, RONNIE C, et al. 435/5. C12Q001/70; C12Q001/68 A01N043/04 A61K031/70 C07H015/12 C07H017/00.
- 55. US20030096776A. New chemically modified oligonucleotides, useful for modulating telomere length of a mammalian chromosome, inhibiting the division of a malignant mammalian cell, or modulating the effects of aging of a mammalian cell. ANDERSON, K P, et al. A61K048/00

C07H021/04 C12N015/85.

□ 56. US20020127634A. Treating condition associated with cell senescence or increased rate of cell proliferation, by administering to cell an agent that derepresses telomerase in the senescent cells or that reduces loss of telomere length. BLACKBURN, E H, et al. G01J003/42 G01N031/00 G01N035/00 G01N035/02.

□ 57. EP 672193B. New modified oligo-nucleotide contg guanine quartet - inhibits activity of viruses, e.g. HIV, and phospholipase A2 and modulates telomere length of chromosomes. ANDERSON, K P, et al. A01N043/04 A01N063/00 A61F006/00 A61K007/40 A61K031/70 A61K031/7125 A61L031/00 A61P031/12 A61P035/00 C07H000/00 C07H015/12 C07H017/00 C07H021/00 C07H021/02 C07H021/04 C12N007/06 C12N009/99 C12N015/09 C12N015/11 C12P019/34 C12Q001/68 C12Q001/70.

[Generate Collection](#)

[Print](#)

Terms	Documents
L8 and (modified) near5 oligonucleotide\$	57

[Prev Page](#) [Next Page](#) [Go to Doc#](#)